Navigation Links
Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value
Date:10/6/2011

NEW YORK, Oct. 6, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value

http://www.reportlinker.com/p0652041/Metabolic-Disorders-Therapeutics-Market-to-2017---Patent-Expiry-of-Lipitor-in-2011-will-Negatively-Impact-Dyslipidemia-Market-Value.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value

Summary

GBI Research, the leading business intelligence provider, has released its latest research "Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value", which provides insights into metabolic disease therapeutics marled until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. The report provides an in-depth analysis of the major metabolic diseases including Diabetes, Obesity and Dyslipidemia. The report also provides the share of generics in global metabolic diseases as well as in each indication market. It also provides the treatment algorithm flow for each three indications. The report examines the global metabolic diseases treatment usage patterns. In addition, the geographical distribution of metabolic diseases and market across the US, the top five countries of Europe and in Japan are provided in the report. The report also includes insights into the metabolic diseases R&D product pipeline and explores the competitive landscape including major players in metabolic disorder therapeutics market. Finally, the report also includes analysis on Mergers and Acquisitions (M&As) and licensing agreements that took place in metabolic disorder therapeutics market.

Scope

- The report analyzes treatment usage patterns, market characterization, pipeline analysis, competitive landscape and key M&A trends in the global metabolic disorder therapeutics market for the three indications that includes Diabetes, Obesity and Dyslipidemia.

- Data and analysis on the metabolic disorder therapeutics market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.

- Annualized market data for the metabolic disorder therapeutics market from 2002 to 2010, with forecasts to 2017 for three indications which includes diabetes, obesity and dyslipidemia

- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.

- Share of the generics in global metabolic disorder therapeutics market and for the market of each indication that is covered in the report.

- Key drivers and restraints that have had a significant impact on the market.

- The competitive landscape of the global metabolic disorder market including top companies benchmarking. The key companies studied in this report are Pfizer Inc., Novo Nordisk, Sanofi, Takeda, Eli Lilly, GlaxoSmithKline and Merck & Co. Inc.

- Key M&A activities and Licensing Agreements that took place in 2009 and 2011 in the metabolic disorder therapeutics market.

Reasons to buy

The report will assist business development and marketing executives to strategize their product launches, by allowing them to -

- Align your product portfolio to the markets with high growth potential.

- Build effective strategies to launch their pipeline products by identifying potential geographies.

- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.

- Develop key strategic initiatives by studying the key strategies of top competitors.

- Device a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.

- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 7

1.2 List of Figures 9

2 Metabolic Disorders Therapeutics Market to 2017 - Introduction 12

2.1 Overview 12

2.2 GBI Research Report Guidance 13

3 Metabolic Disorders Therapeutics Market to 2017 - Market Characterization 14

3.1 Introduction 14

3.2 Revenue Forecast for the Metabolic Disorders Therapeutics Market to 2017 15

3.2.1 Revenues 15

3.2.2 Revenue by Country 16

3.2.3 Generic Share 18

3.2.4 Annual Cost of Treatment (ACT) 19

3.3 Treatment Usage Patterns 20

3.3.1 Diseased Population 22

3.3.2 Treatment Seeking Population 23

3.3.3 Diagnosed Population 24

3.3.4 Prescription Population 25

3.4 Drivers and Restraints of the Global Metabolic Disorders Therapeutics Market 26

3.4.1 Drivers for the Metabolic Disorders Therapeutics Market 26

3.4.2 Restraints for the Metabolic Disorders Therapeutics Market 27

4 Metabolic Disorders Therapeutics Market to 2017 - Geographical Landscape 28

4.1 Revenue Analysis by Geography 28

4.2 The US 30

4.2.1 Revenue 30

4.2.2 Annual Cost of Treatment 31

4.2.3 Treatment Usage Pattern 32

4.3 Top Five Countries of Europe 37

4.3.1 Revenue 37

4.3.2 Annual Cost of Treatment 39

4.3.3 Treatment Usage Pattern 40

4.4 Japan 45

4.4.1 Revenue 45

4.4.2 Annual Cost of Treatment 46

4.4.3 Treatment Usage Pattern 47

5 Metabolic Disorders Therapeutics Market to 2017 - Diabetes Market 52

5.1 Introduction 52

5.2 Market Forecasts 52

5.2.1 Revenue by Country 54

5.2.2 Generic Share 55

5.3 Annual Cost of Treatment 56

5.4 Treatment Flow Algorithm 57

5.5 Treatment Usage Patterns 58

5.5.1 Diseased Population 59

5.5.2 Treatment Seeking Population 60

5.5.3 Diagnosed Population 61

5.5.4 Prescription Population 62

5.6 Major Marketed Products 63

5.7 Drivers and Restraints of the Diabetes Market 64

5.7.1 Drivers of the Diabetes Market 64

5.7.2 Restraints of the Diabetes Market 65

6 Metabolic Disorders Therapeutics Market to 2017 - Obesity Market 66

6.1 Introduction 66

6.2 Market Forecasts 66

6.2.1 Revenue by Country 67

6.2.2 Generic Share 68

6.3 Annual Cost of Treatment 69

6.4 Treatment Flow Algorithm 70

6.5 Treatment Usage Patterns 71

6.5.1 Diseased Population 73

6.5.2 Treatment Seeking Population 74

6.5.3 Diagnosed Population 75

6.5.4 Prescription Population 76

6.6 Major Marketed Products 77

6.7 Drivers and Restraints of the Obesity Market 77

6.7.1 Drivers of the Obesity Market 77

6.7.2 Restraints of the Obesity Market 78

7 Metabolic Disorders Therapeutics Market to 2017 - Dyslipidemia Market 79

7.1 Introduction 79

7.2 Market Forecasts 79

7.2.1 Revenue by Country 80

7.2.2 Generic Share 81

7.3 Annual Cost of Treatment 82

7.4 Treatment Flow Algorithm 83

7.5 Treatment Usage Patterns 84

7.5.1 Diseased Population 85

7.5.2 Treatment Seeking Population 86

7.5.3 Diagnosed Population 87

7.5.4 Prescription Population 88

7.6 Major Marketed Products 89

7.7 Drivers and Restraints of the Dyslipidemia Market 89

7.7.1 Drivers of the Dyslipidemia Market 89

7.7.2 Restraints of the Dyslipidemia Market 89

8 Metabolic Disorders Therapeutics Market to 2017 - Pipeline Analysis 90

8.1 Introduction 90

8.2 Diabetes: Research and Development Pipeline 92

8.2.1 Overview 92

8.2.2 Pipeline by Clinical Phases of Development 92

8.3 Obesity: Research and Development Pipeline 108

8.3.1 Overview 108

8.3.2 Pipeline by Clinical Phases of Development 108

8.4 Dyslipidemia: Research and Development Pipeline 113

8.4.1 Overview 113

8.4.2 Pipeline by Clinical Phases of Development 114

8.5 Profiles of Promising Drugs in the Diabetes Market 118

8.5.1 rhGAD65 (Diamyd) 118

8.5.2 DiaPep277 119

8.5.3 Otelixizumab 119

8.5.4 BMS-512148 (dapagliflozin) 120

8.5.5 D-Tagatose 121

8.5.6 JNJ-28431754 (canagliflozin) 121

8.5.7 Teplizumab 122

8.5.8 Lixisenatide 123

8.6 Profiles of Promising Drugs in the Obesity Market 124

8.6.1 Contrave (Buropion SR + Naltrexone) 124

8.6.2 Victoza (liraglutide) 124

8.6.3 Cametor (cetilistat) 126

8.7 Profiles of Promising Drugs in the Dyslipidemia Market 127

8.7.1 RG1658 (Dalcetrapib, JTT-705, RO4607381) 127

8.7.2 MK-0524A (Cordaptive, niacin + laropiprant) 128

8.7.3 AMR101 (LAX-101, Miraxion) 129

8.7.4 MK-0859 (anacetripib) 130

9 Metabolic Disorders Therapeutics Market to 2017 - Competitive Landscape 131

9.1 Company Profiles for Metabolic Disorders 131

9.1.1 Pfizer Inc. 131

9.1.2 Novo Nordisk 133

9.1.3 Sanofi 134

9.1.4 Takeda 136

9.1.5 Eli Lilly 137

9.1.6 GlaxoSmithKline (GSK) 138

9.1.7 Merck & Co Inc 139

9.1.8 Amylin Pharmaceuticals 141

10 Metabolic Disorders Therapeutics Market to 2017 - Strategic Consolidations 142

10.1 Mergers and Acquisitions 142

10.1.1 Segmentation by Indication 142

10.1.2 Segmentation by Deal Value 145

10.1.3 Segmentation by Geography 147

10.2 Co-Development Deals 148

10.2.1 Summary of Co-Development Deals 151

10.3 Licensing Deals 154

10.3.1 Summary of Licensing Deals 159

11 Metabolic Disorders Therapeutics Market to 2017 - Appendix 162

11.1 Market Definitions 162

11.2 Abbreviations 162

11.3 Research Methodology 164

11.3.1 Coverage 164

11.3.2 Secondary Research 164

11.3.3 Primary Research 165

11.3.4 Therapeutic Landscape 165

11.3.5 Geographical Landscape 168

11.3.6 Pipeline Analysis 168

11.3.7 Competitive Landscape 168

11.4 Expert Panel Validation 168

11.5 Contact Us 168

11.6 Disclaimer 169

11.7 Sources 169

1.1 List of Tables

Table 1: Metabolic Disorders Therapeutics Market, Global, Obesity Classification by Body Mass Index (BMI), 2010 14

Table 2: Metabolic Disorders Therapeutics Market, Global, Revenue ($bn), 2002-2010 15

Table 3: Metabolic Disorders Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017 16

Table 4: Metabolic Disorders Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010 17

Table 5: Metabolic Disorders Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2017 17

Table 6: Metabolic Disorders Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010 19

Table 7: Metabolic Disorders Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017 19

Table 8: Metabolic Disorders Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2010 21

Table 9: Metabolic Disorders Therapeutics Market, Global, Treatment Usage Patterns (million), 2010-2017 21

Table 10: Metabolic Disorders Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010 28

Table 11: Metabolic Disorders Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2017 29

Table 12: Metabolic Disorders Therapeutics Market, The US, Revenue ($bn), 2002-2010 30

Table 13: Metabolic Disorders Therapeutics Market, The US, Revenue Forecasts ($bn), 2010-2017 30

Table 14: Metabolic Disorders Therapeutics Market, The US, Annual Cost of Therapy ($), 2002-2010 31

Table 15: Metabolic Disorders Therapeutics Market, The US, Annual Cost of Therapy ($), 2010-2017 31

Table 16: Metabolic Disorders Therapeutics Market, The US, Treatment Usage Pattern (million), 2002-2010 32

Table 17: Metabolic Disorders Therapeutics Market, The US, Treatment Usage Pattern (million), 2010-2017 33

Table 18: Metabolic Disorders Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2002-2010 37

Table 19: Metabolic Disorders Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2010-2017 38

Table 20: Metabolic Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2002-2010 39

Table 21: Metabolic Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2010-2017 39

Table 22: Metabolic Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2002-2010 40

Table 23: Metabolic Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2010-2017 41

Table 24: Metabolic Disorders Therapeutics Market, Japan, Revenue ($bn), 2002-2010 45

Table 25: Metabolic Disorders Therapeutics Market, Japan, Revenue Forecasts ($bn), 2010-2017 45

Table 26: Metabolic Disorders Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002-2010 46

Table 27: Metabolic Disorders Therapeutics Market, Japan, Annual Cost of Therapy ($), 2010-2017 46

Table 28: Metabolic Disorders Therapeutics Market, Japan, Treatment Usage Pattern (million), 2002-2010 47

Table 29: Metabolic Disorders Therapeutics Market, Japan, Treatment Usage Pattern (million), 2010-2017 48

Table 30: Diabetes Therapeutics Market, Global, Revenue ($bn), 2002-2010 53

Table 31: Diabetes Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017 53

Table 32: Diabetes Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010 54

Table 33: Diabetes Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2017 55

Table 34: Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010 56

Table 35: Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017 56

Table 36: Diabetes Therapeutics Market, Global, Treatment Usage Pattern (million), 2002-2010 58

Table 37: Diabetes Therapeutics Market, Global, Treatment Usage Pattern (million), 2010-2017 59

Table 38: Diabetes Therapeutics Market, Global, Major Drugs, 2009-2010 64

Table 39: Obesity Therapeutics Market, Global, Revenue ($bn), 2002-2010 66

Table 40: Obesity Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017 67

Table 41: Obesity Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010 67

Table 42: Obesity Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2017 68

Table 43: Obesity Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010 69

Table 44: Obesity Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017 69

Table 45: Obesity Therapeutics Market, Global, Treatment Usage Pattern (million), 2002-2010 72

Table 46: Obesity Therapeutics Market, Global, Treatment Usage Pattern (million), 2010-2017 72

Table 47: Obesity Therapeutics Market, Global, Major Drugs, 2002-2017 77

Table 48: Dyslipidemia Therapeutics Market, Global, Revenue ($bn), 2002-2010 79

Table 49: Dyslipidemia Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017 80

Table 50: Dyslipidemia Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010 80

Table 51: Dyslipidemia Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2017 81

Table 52: Dyslipidemia Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010 82

Table 53: Dyslipidemia Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017 82

Table 54: Dyslipidemia Therapeutics Market, Global, Treatment Usage Pattern (million), 2002-2010 84

Table 55: Dyslipidemia Therapeutics Market, Global, Treatment Usage Pattern (million), 2010-2017 85

Table 56: Dyslipidemia Therapeutics Market, Global, Major Drugs, 2002-2017 89

Table 57: Diabetes Therapeutics Market, Global, Pre-Clinical/Discovery Phase, 2010 93

Table 58: Diabetes Therapeutics Market, Global, Phase I, 2010 97

Table 59: Diabetes Therapeutics Market, Global, Phase II, 2010 101

Table 60: Diabetes Therapeutics Market, Global, Phase III, 2010 105

Table 61: Diabetes Therapeutics Market, Global, NDA/Filed Molecules, 2010 107

Table 62: Obesity Therapeutics Market, Global, Pre-Clinical/Discovery Phase, 2010 109

Table 63: Obesity Therapeutics Market, Global, Phase I, 2010 111

Table 64: Obesity Therapeutics Market, Global, Phase II, 2010 112

Table 65: Obesity Therapeutics Market, Global, Phase III, 2010 112

Table 66: Obesity Therapeutics Market, Global, NDA/Filed Molecules, 2010 112

Table 67: Dyslipidemia Therapeutics Market, Global, Pre-Clinical/Discovery Phase, 2010 114

Table 68: Dyslipidemia Therapeutics Market, Global, Phase I, 2010 115

Table 69: Dyslipidemia Therapeutics Market, Global, Phase II, 2010 116

Table 70: Dyslipidemia Therapeutics Market, Global, Phase III, 2010 117

Table 71: Metabolic Disorders Therapeutics Market, M&A Deals, 2009-2011 143

Table 72: Metabolic Disorders Therapeutics Market, M&A Top Deals by Value ($m), 2009-2011 146

Table 73: Metabolic Disorders Therapeutics Market, Co-Development, By Geography, 2009-2011 149

Table 74: Metabolic Disorders Therapeutics Market, Licensing Deals, By Geography, 2009-2011 155

1.2 List of Figures

Figure 1: Metabolic Disorders Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 14

Figure 2: Metabolic Disorders Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2017 15

Figure 3: Metabolic Disorders Therapeutics Market, Global, Generic Share, 2010 and 2017 17

Figure 4: Metabolic Disorders Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2017 18

Figure 5: Metabolic Disorders Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2017 19

Figure 6: Metabolic Disorders Therapeutics Market, Global, Diseased Population (million), 2002-2017 21

Figure 7: Metabolic Disorders Therapeutics Market, Global, Treatment Seeking Population (million), 2002-2017 22

Figure 8: Metabolic Disorders Therapeutics Market, Global, Diagnosis Population (million), 2002-2017 23

Figure 9: Metabolic Disorders Therapeutics Market, Global, Prescription Population (million), 2002-2017 24

Figure 10: Metabolic Disorders Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2017 27

Figure 11: Metabolic Disorders Therapeutics Market, The US, Revenue Forecasts ($bn), 2002-2017 29

Figure 12: Metabolic Disorders Therapeutics Market, The US, Annual Cost of Therapy ($), 2002-2017 30

Figure 13: Metabolic Disorders Therapeutics Market, The US, Treatment Usage Pattern (million), 2002-2017 31

Figure 14: Metabolic Disorders Therapeutics Market, The US, Diseased Population (million), 2002-2017 32

Figure 15: Metabolic Disorders Therapeutics Market, The US, Treatment Seeking Population (million), 2002-2017 33

Figure 16: Metabolic Disorders Therapeutics Market, The US, Diagnosed Population (million), 2002-2017 34

Figure 17: Metabolic Disorders Therapeutics Market, The US, Prescription Population (million), 2002-2017 35

Figure 18: Metabolic Disorders Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2002-2017 36

Figure 19: Metabolic Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2002-2017 38

Figure 20: Metabolic Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2002-2017 39

Figure 21: Metabolic Disorders Therapeutics Market, Top Five Countries of Europe, Diseased Population (million), 2002-2017 40

Figure 22: Metabolic Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Seeking Population (million), 2002-2017 41

Figure 23: Metabolic Disorders Therapeutics Market, Top Five Countries of Europe, Diagnosed Population (million), 2002-2017 42

Figure 24: Metabolic Disorders Therapeutics Market, Top Five Countries of Europe, Prescription Population (million), 2002-2017 43

Figure 25: Metabolic Disorders Therapeutics Market, Japan, Revenue Forecasts ($bn), 2002-2017 44

Figure 26: Metabolic Disorders Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002-2017 45

Figure 27: Metabolic Disorders Therapeutics Market, Japan, Treatment Usage Pattern (million), 2002-2017 46

Figure 28: Metabolic Disorders Therapeutics Market, Japan, Diseased Population (million), 2002-2017 47

Figure 29: Metabolic Disorders Therapeutics Market, Japan, Treatment Seeking Population (million), 2002-2017 48

Figure 30: Metabolic Disorders Therapeutics Market, Japan, Diagnosed Population (million), 2002-2017 49

Figure 31: Metabolic Disorders Therapeutics Market, Japan, Prescription Population (million), 2002-2017 50

Figure 32: Diabetes Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 52

Figure 33: Diabetes Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2017 53

Figure 34: Diabetes Therapeutics Market, Global, Generic Share, 2010 and 2017 54

Figure 35: Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2017 55

Figure 36: Diabetes Therapeutics Market, Treatment Flow Algorithm 56

Figure 37: Diabetes Therapeutics Market, Global, Treatment Usage Pattern (million), 2002-2017 57

Figure 38: Diabetes Therapeutics Market, Global, Diseased Population (million), 2002-2017 58

Figure 39: Diabetes Therapeutics Market, Global, Treatment Seeking Population (million), 2002-2017 59

Figure 40: Diabetes Therapeutics Market, Global, Diagnosed Population (million), 2002-2017 60

Figure 41: Diabetes Therapeutics Market, Global, Prescription Population (million), 2002-2017 61

Figure 42: Diabetes Therapeutics Market, Global, Major Companies, Revenue ($bn), 2009-2010 62

Figure 43: Obesity Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 65

Figure 44: Obesity Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2017 66

Figure 45: Obesity Therapeutics Market, Global, Generic Share, 2010 and 2017 67

Figure 46: Obesity Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2017 68

Figure 47: Obesity Therapeutics Market, Treatment Flow Algorithm - 1 69

Figure 48: Obesity Therapeutics Market, Treatment Flow Algorithm - 2 69

Figure 49: Obesity Therapeutics Market, Global, Treatment Usage Pattern (million), 2002-2017 70

Figure 50: Obesity Therapeutics Market, Global, Diseased Population (million), 2002-2017 72

Figure 51: Obesity Therapeutics Market, Global, Treatment Seeking Population (million), 2002-2017 73

Figure 52: Obesity Therapeutics Market, Global, Diagnosed Population (million), 2002-2017 74

Figure 53: Obesity Therapeutics Market, Global, Prescription Population (million), 2002-2017 75

Figure 54: Dyslipidemia Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 78

Figure 55: Dyslipidemia Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2017 79

Figure 56: Dyslipidemia Therapeutics Market, Global, Generic Share, 2010 and 2017 80

Figure 57: Dyslipidemia Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2017 81

Figure 58: Dyslipidemia Therapeutics Market, Treatment Flow Algorithm 82

Figure 59: Dyslipidemia Therapeutics Market, Global, Treatment Usage Pattern (million), 2002-2017 83

Figure 60: Dyslipidemia Therapeutics Market, Global, Diseased Population (million), 2002-2017 84

Figure 61: Dyslipidemia Therapeutics Market, Global, Treatment Seeking Population (million), 2002-2017 85

Figure 62: Dyslipidemia Therapeutics Market, Global, Diagnosed Population (million), 2002-2017 86

Figure 63: Dyslipidemia Therapeutics Market, Global, Prescription Population (million), 2002-2017 87

Figure 64: Metabolic Disorders Therapeutics Market, Global, R&D Pipeline by Indication (%), 2010 89

Figure 65: Metabolic Disorders Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010 90

Figure 66: Diabetes Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010 91

Figure 67: Obesity Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010 107

Figure 68: Dyslipidemia Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010 112

Figure 69: Metabolic Disorders Therapeutics Market, Company Shares, 2010 130

Figure 70: Metabolic Disorders Therapeutics Market, Pfizer Inc., SWOT Analysis, 2010 131

Figure 71: Metabolic Disorders Therapeutics Market, Novo Nordisk, SWOT Analysis, 2010 133

Figure 72: Metabolic Disorders Therapeutics Market, Sanofi, SWOT Analysis, 2010 134

Figure 73: Metabolic Disorders Therapeutics Market, Takeda, SWOT Analysis, 2010 135

Figure 74: Metabolic Disorders Therapeutics Market, Eli Lilly, SWOT Analysis, 2010 137

Figure 75: Metabolic Disorders Therapeutics Market, GSK, SWOT Analysis, 2010 138

Figure 76: Metabolic Disorders Therapeutics Market, Merck & Co. Inc., SWOT Analysis, 2010 139

Figure 77: Metabolic Disorders Therapeutics Market, Amylin Pharmaceuticals, SWOT Analysis, 2010 140

Figure 78: Metabolic Disorders Therapeutics Market, M&A, by Indication, 2010 141

Figure 79: Metabolic Disorders Therapeutics Market, M&A Deals by Deal Value ($m), 2009-2011 144

Figure 80: Metabolic Disorders Therapeutics Market, M&A Deals, By Geography, 2009-2011 146

Figure 81: Metabolic Disorders Therapeutics Market, Co-Development, By Indications, 2009-2011 147

Figure 82: Metabolic Disorders Therapeutics Market, Licensing Deals, By Geography, 2009-2011 158

Figure 83: GBI Research Market Forecasting Model 166

Companies mentioned

Pfizer Inc.

Novo Nordisk

Sanofi

Takeda

Eli Lilly

GlaxoSmithKline (GSK)

Merck & Co Inc

Amylin Pharmaceuticals

To order this report:

Pathology Industry: Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value

Pathology Business News

More  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Metabolic Solutions Development Company Reports Positive Top-Line Results From Phase 2a Study of Its Second Compound to Treat Type 2 Diabetes
2. Regulus Therapeutics to Present New Advancements in microRNA Therapeutics for Treatment of Metabolic Diseases and Cancer
3. Study Uncovers Key Success Factors and Common Failure Points for Launching New Metabolic Products in Todays Competitive Healthcare Market
4. BioRestorative Therapies Signs License Agreement With University of Utah to Obtain Adipose (Fat) Tissue for its ThermoStem Program to Treat Obesity and Metabolic Disorders
5. Metabolic Solutions Development Company to Present Recent Findings on the Therapeutic Potential of Increasing Brown Fat in the Treatment of Diabetes at Annual American Diabetes Association Conference
6. GT Life Sciences Broadens Intellectual Property Portfolio with Issuance of U.S. Patent on Core Computational Systems and Methods for Genomic-based Metabolic Modeling
7. Creating a Road Map for Successful Metabolic New Product Launches
8. Cytotech Labs Unravels Hallmark Insight Into Metabolic Control of Cancer, Presents Work at Major AACR Cancer Meeting
9. Metabolic Solutions Development Company Launches Phase 2a Trial of Its Second Compound to Treat Type 2 Diabetes
10. Dave Anderson and William Thomsen Join SRI Internationals Center for Advanced Drug Research to Lead Programs in Proteomics and Metabolic Disease Drug Discovery
11. Bionovo Announces Publication Describing How Metabolic Adaptability Contributes to the Metastasis of Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... , May 27, 2016 ... biopharmaceutical company focused on late-stage drug development, today ... Pharma of pivotal batches required for registration ... Administration (FDA). This follows Kitov,s announcement ... trial successfully met its primary efficacy endpoint. ...
(Date:5/26/2016)... 2016 TARE (Transarterial Radio-embolization) ... Savings and Overall Decreased Use of Hospital ... international specialist healthcare company, has today announced the ... Meeting of ISPOR (International Society for Pharmacoeconomics and ... (HCC) using yttrium-90 glass microspheres is associated with ...
(Date:5/25/2016)... , Deutschland und GERMANTOWN, Maryland ... Zusammenarbeit mit Therawis bedient dringenden ... Brustkrebs   QIAGEN N.V. (NASDAQ: ... heute bekannt, eine Lizenz- und Entwicklungsvereinbarung mit Therawis ... für die Onkologie eingegangen zu sein. Ein erstes ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... ... Southland Log Homes , designer and manufacturer of America’s Favorite Log ... be found on its website at SouthlandLogHomes.com. , The designs of the wood ... craftsmanship of timber post and beam construction. The result is a barn that ...
(Date:5/27/2016)... York, NY (PRWEB) , ... May 27, 2016 , ... ... factors of a stroke, which we as a society can control and change. , ... stroke occurs nearly every 40 seconds within the United States. Plus, with an estimated ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and employees ... which come courtesy of leaders in the nursing and health care industry. It also ... and associations—namely Abilene Christian University. , As the nursing industry is coming out ...
(Date:5/26/2016)... Hampshire (PRWEB) , ... May 26, 2016 , ... ... care products, has been honored with a 2016 When Work Works Award for its ... award, part of the national When Work Works project administered by the Families and ...
(Date:5/26/2016)... ... ... On Memorial Day, Hope For Heroes and USA Medical Card ... the country. The nonprofit Hope For Heroes partnered with the leading provider of ... disabled military veterans, as well as police, firemen, and EMS professionals across the country, ...
Breaking Medicine News(10 mins):